The research, led by Xueping Wang, Zhewei Kang and colleagues under the corresponding authorship of Weihua Yue, took an exploratory but systematic approach. Rather than asking which genes contribute to schizophrenia risk in general, the team asked a pharmacogenomic question: which genetic differences predict how well negative symptoms respond to medication? They focused on two atypical antipsychotics, aripiprazole and ziprasidone, and tracked patients over a six-week course of monotherapy, meaning each participant received only one of the two drugs, without other antipsychotic medications complicating the picture.

The clinical yardstick in the study was the Positive and Negative Syndrome Scale, or PANSS, one of the most widely used instruments in schizophrenia research. The PANSS breaks a patient’s symptoms into positive items, such as hallucinations and suspiciousness, and negative items, such as emotional blunting and avolition. The researchers measured the reduction in the PANSS negative subscale score, abbreviated PANSS-N, after six weeks of treatment. A large drop in this score signals meaningful recovery of motivation, expressiveness and social engagement — the domains that most strongly determine long-term functional prognosis.

To find genetic predictors of that recovery, the team performed a genome-wide association study, or GWAS, in Han Chinese patients with schizophrenia. A GWAS scans hundreds of thousands of genetic positions across the genome, looking for variants — single-letter differences in DNA called single nucleotide polymorphisms — that statistically track with the trait of interest. In this case, the trait was the degree of PANSS-N reduction. The scan produced a standout result: a variant known as rs28502452 in the MCTP2 gene showed an association with negative symptom improvement, reaching a significance level of P = 8.01 × 10⁻⁶. In the language of statistics, this means the probability of seeing such an association by chance alone is roughly eight in a million — not genome-wide definitive on its own, but a striking signal for an exploratory analysis.

MCTP2 is not a random stretch of DNA. The gene encodes multiple C2 domain-containing transmembrane proteins, molecular scaffolds found at synapses, the junctions where neurons communicate with one another. C2 domains are calcium-binding modules, which immediately hints at the gene’s functional territory: calcium is the universal trigger for neurotransmitter release, and synaptic calcium signaling is central to learning, memory and perception. Previous work has implicated MCTP2 in higher cognitive functions, and the gene has drawn particular attention for its role in facial recognition — the ability to identify individuals and read expressions from faces, a skill that depends on a specialized network of brain regions and one that is often impaired in neurodevelopmental and neurodegenerative conditions.

The association became more compelling when the researchers layered expression data on top of the genetic result. Using expression quantitative trait loci, or eQTL, analysis — a technique that links DNA variants to the activity level of nearby or distant genes — they determined that the alleles associated with greater PANSS-N reduction were the same alleles linked to higher MCTP2 expression. In other words, patients whose genomes drive stronger production of the MCTP2 protein responded better to treatment on the negative symptom dimension. This directionality matters, because it suggests a biologically coherent story rather than a statistical fluke: more MCTP2, better cognitive and emotional function, greater improvement when the synaptic chemistry is adjusted by medication.

To test whether MCTP2’s role extends beyond schizophrenia, the team examined gene expression patterns in three disorders: schizophrenia, Alzheimer’s disease and autism spectrum disorder. Across all three, the analyses supported a positive regulatory role for MCTP2 in normal cognitive function — that is, wherever MCTP2 activity is diminished, cognition tends to suffer, and the gene’s expression profile behaves as a guardian of cognitive health rather than a disease driver. This cross-disorder consistency is notable because schizophrenia, Alzheimer’s and autism are very different conditions, yet all three involve disruptions of synaptic function and higher cognition, and all three may converge on the same molecular machinery.

The researchers then mapped the protein interaction landscape around MCTP2. Protein–protein interaction networks chart which gene products physically or functionally cooperate inside cells, and the analysis revealed a tightly connected cluster centered on calcium signaling, featuring the genes SLITRK5, NCALD and CPNE5. SLITRK5 is a synaptic protein known to shape dendritic growth and excitatory synapse development; NCALD, or neurocalcin delta, is a calcium sensor expressed in neurons; CPNE5, a copine family member, is also calcium-dependent. The cluster’s identity dovetailed with the network pharmacology analysis, a computational method that maps the molecular targets of a drug across cellular pathways. For both aripiprazole and ziprasidone, the calcium signaling pathway emerged as a major component of the drugs’ pharmacological networks — meaning the very pathway housing MCTP2’s interaction partners is one that the two medications themselves engage.

Perhaps the most intriguing structural finding concerns two synaptic proteins, SLITRK5 and PTPRD, which the analysis suggests may regulate the interaction network connecting MCTP2 with another gene, BTBD9. Both MCTP2 and BTBD9 are described in the study as high-risk genes for the improvement of negative symptoms, and the possibility that SLITRK5 and PTPRD act as intermediaries — molecular brokers wiring MCTP2 and BTBD9 into a shared circuit — offers a concrete hypothesis for how genetic variation at multiple loci could converge on a single functional outcome: the recovery of motivation, affect and social engagement under antipsychotic treatment.

The authors are careful to frame the work as exploratory, and the association signal, while strong for a first pass, will need replication in independent cohorts before it can inform clinical practice. The study population was exclusively Han Chinese, and pharmacogenomic associations can differ across ancestries, so international replication is an obvious next step. Nevertheless, the findings sketch a foundation for three intertwined research agendas: understanding the biology of negative symptoms, which remain the least treatable facet of schizophrenia; dissecting the genetics of cognitive impairment across psychiatric and neurodegenerative disease; and developing targeted therapies that could one day be matched to a patient’s genotype. If the MCTP2-centered calcium signaling network holds up under scrutiny, it could shift the field’s attention toward a mechanistic axis that connects synaptic calcium dynamics, social cognition and drug response — and toward a future in which a simple genetic test helps clinicians predict, before the first prescription is written, which patients are most likely to reclaim the motivation and emotional warmth that schizophrenia so often takes away.

Subject of Research: Genetic and expression analysis of MCTP2 in relation to negative symptom improvement in schizophrenia patients treated with antipsychotics

Article Title: Exploratory genetic and expression analysis identifies MCTP2 associated with negative symptom improvement in schizophrenia

Article References: Wang, X., Kang, Z., Zhang, Y., Sun, Y., Lu, T., Yan, H., & Yue, W. (2026). Exploratory genetic and expression analysis identifies MCTP2 associated with negative symptom improvement in schizophrenia. Schizophrenia. https://doi.org/10.1038/s41537-026-00806-2

Image Credits: AI Generated

DOI: 10.1038/s41537-026-00806-2

Keywords: schizophrenia, MCTP2, negative symptoms, pharmacogenomics, GWAS, aripiprazole, ziprasidone, PANSS, calcium signaling, synaptic proteins, eQTL, cognitive function